Immatics has innovative TCR therapies, strong cash position, and expanding clinical pipeline targeting solid tumors. Read for ...
The median estimate for 2026 is for the market to rise to 7500 next year, which would be a disappointing return of just 9.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback